Global X S&P Biotech ETF (ASX:CURE)
Australia
· Delayed Price · Currency is AUD 43.97
+0.05 (0.11%)
Jul 9, 2025, 4:10 PM AEST
-4.97% (1Y)
| Assets | 30.15M |
| Expense Ratio | 0.45% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -4.93% |
| Volume | 671 |
| Open | 44.27 |
| Previous Close | 43.92 |
| Day's Range | 43.97 - 44.27 |
| 52-Week Low | 38.76 |
| 52-Week High | 54.72 |
| Beta | 0.78 |
| Holdings | 10 |
| Inception Date | Nov 8, 2018 |
About CURE
The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.
Asset Class Equity
Category Health Care
Stock Exchange Australian Securities Exchange
Ticker Symbol CURE
Provider Global X
Index Tracked S&P Biotechnology Select Industry
Performance
CURE had a total return of -4.93% in the past year, including dividends. Since the fund's inception, the average annual return has been 1.44%.
Top 10 Holdings
24.68% of assets| Name | Symbol | Weight |
|---|---|---|
| Alnylam Pharmaceuticals, Inc. | ALNY | 2.61% |
| Insmed Incorporated | INSM | 2.59% |
| Exelixis, Inc. | EXEL | 2.55% |
| United Therapeutics Corporation | UTHR | 2.51% |
| Neurocrine Biosciences, Inc. | NBIX | 2.49% |
| Regeneron Pharmaceuticals, Inc. | REGN | 2.43% |
| Vertex Pharmaceuticals Incorporated | VRTX | 2.39% |
| Natera, Inc. | NTRA | 2.38% |
| Incyte Corporation | INCY | 2.38% |
| Halozyme Therapeutics, Inc. | HALO | 2.35% |